

Loxo Oncology Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 07-Mar-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 8

 Phase 1 Clinical..... 9

 Discovery..... 12

[Return to Table of Contents](#)

Loxo Oncology Inc

COMPANY OVERVIEW

Company Name	Loxo Oncology Inc
Parent Company Name	Loxo Oncology Inc
Website	http://www.loxooncology.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	0
Number of Patents as Owner	0
Number of Patents as Third Party	0
Number of Deals	1
Key Indications	Cancer
Key Target-based Actions	FGF receptor antagonist,Flt3 tyrosine kinase inhibitor,Ret tyrosine kinase receptor inhibitor
Key Technologies	Small molecule therapeutic

COMPANY PROFILE

SUMMARY

Loxo Oncology, incorporated in Delaware in May 2013, is a biopharmaceutical company established and funded by Aisling Capital focused on cancer therapeutics.

FINANCIAL

In August 2014, the company was to sell 230,769 shares of its common stock, at a price of \$13 per share,through a private placement; in September 2014, the sale was completed.

In August 2014, the company priced its initial public offering of 5,261,538 shares of its common stock, at \$13 per share. The underwriters were granted a 30-day overallotment option to purchase up to an additional 789,230 shares of common stock. At that time, the shares began trading on National Association of Securities Dealers Automated Quotations under the symbol "LOXO"; in September 2014, the offering was closed.

In May 2014, the company raised \$24 million from a series B private financing round.

In October 2013, the company raised \$33 million from a series A financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	4	0	4

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	3

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	1	0	1

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

LOXO-101

LOXO-101 SNAPSHOT

Drug Name	LOXO-101
Key Synonyms	
Originator Company	Array BioPharma Inc
Active Companies	Loxo Oncology Inc;Array BioPharma Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Cancer
Target-based Actions	Tropomyosin inhibitor;Protein tyrosine kinase inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	03-Mar-2015

LOXO-101 DEVELOPMENT PROFILE

SUMMARY

Array BioPharma and licensee Loxo Oncology are developing LOXO-101, a lead tyrosine kinase inhibitor, targeting an oncogenic activating mutation, for the potential oral treatment of cancer,. In April 2014, a phase Ia/Ib trial was initiated in the US.

LOXO-101 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Array BioPharma Inc	Cancer	US	Phase 1 Clinical	24-Apr-2014
Loxo Oncology Inc	Cancer	US	Phase 1 Clinical	24-Apr-2014

[Return to Table of Contents](#)



LOXO-101 DRUG NAMES

Names	Type
LOXO-101	Research Code
tyrosine kinase inhibitor (oral, cancer), Array BioPharma/Loxo Oncology	
oncogenic activating mutation-targeting compound (cancer), Array BioPharma/ Loxo Oncology	

LOXO-101 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Advanced solid tumor											
0	0	0	0	1	1	0	0	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	0	0	0	1	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

LOXO-101 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Loxo Oncology Inc	0	0	1	0	1
Array BioPharma Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

Loxo-103

Loxo-103 SNAPSHOT

Drug Name	Loxo-103
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Loxo Oncology Inc;Array BioPharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	FGF receptor antagonist
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

Loxo-103 DEVELOPMENT PROFILE

SUMMARY

Loxo Oncology and Array BioPharma are investigating Loxo-103, presumed to be a fibroblast growth factor receptor (FGFR) inhibitor, for the potential treatment of cancer. In March 2014, the program was listed as being in preclinical development. In March 2015, this was still the case.

Loxo-103 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Array BioPharma Inc	Cancer	US	Discovery	28-Mar-2014
Loxo Oncology Inc	Cancer	US	Discovery	28-Mar-2014

Loxo-103 DRUG NAMES


Names	Type
FGFR inhibitor (cancer), Loxo Oncology/Array BioPharma	
Loxo-103	Research Code

[Return to Table of Contents](#)

Loxo-103 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Loxo Oncology Inc	0	0	1	0	1
Array BioPharma Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

Loxo-104

Loxo-104 SNAPSHOT

Drug Name	Loxo-104
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Array BioPharma Inc;Loxo Oncology Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Flt3 tyrosine kinase inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

Loxo-104 DEVELOPMENT PROFILE

SUMMARY

Loxo Oncology and Array BioPharma are investigating Loxo-104, presumed to be a FMS-like tyrosine kinase 3 (FLT3) inhibitor, for the potential treatment of cancer including acute myeloid leukemia . In March 2014, the program was listed as being in preclinical development. In March 2015, this was still the case.

Loxo-104 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Array BioPharma Inc	Cancer	US	Discovery	28-Mar-2014
Loxo Oncology Inc	Cancer	US	Discovery	28-Mar-2014

Loxo-104 DRUG NAMES

Names	Type
FLT3 inhibitor (cancer), Loxo Oncology/Array BioPharma	
Loxo-104	Research Code


[Return to Table of Contents](#)



Loxo-104 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Loxo Oncology Inc	0	0	1	0	1
Array BioPharma Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

Loxo-102

Loxo-102 SNAPSHOT

Drug Name	Loxo-102
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Loxo Oncology Inc;Array BioPharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Ret tyrosine kinase receptor inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

Loxo-102 DEVELOPMENT PROFILE

SUMMARY

Loxo Oncology and Array BioPharma are investigating Loxo-102, presumed to be a rearranged during transfection (RET) inhibitor, for the potential treatment of cancer. In March 2014, the program was listed as being in preclinical development. In March 2015, this was still the case.

Loxo-102 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Array BioPharma Inc	Cancer	US	Discovery	28-Mar-2014
Loxo Oncology Inc	Cancer	US	Discovery	28-Mar-2014

Loxo-102 DRUG NAMES

Names	Type
RET inhibitor (cancer), Loxo Oncology/Array BioPharma	
Loxo-102	Research Code


[Return to Table of Contents](#)



Loxo-102 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Loxo Oncology Inc	0	0	1	0	1
Array BioPharma Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

